UK Markets open in 4 hrs 10 mins

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Delayed price. Currency in USD
Add to watchlist
40.58-1.86 (-4.38%)
At close: 4:00PM EDT

40.58 0.00 (0.00%)
After hours: 7:34PM EDT

People also watch
CLVSACADJUNOKITEPTCT
Full screen
Previous close42.44
Open42.51
Bid39.50 x 2000
Ask40.90 x 100
Day's range40.12 - 42.77
52-week range23.51 - 63.73
Volume4,134,949
Avg. volume2,417,026
Market cap2.23B
Beta2.20
PE ratio (TTM)-16.75
EPS (TTM)N/A
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
Trade prices are not sourced from all markets
  • This Biotech Got A Price Hike, But Seesawed After A Three-Day Run
    Investor's Business Daily3 days ago

    This Biotech Got A Price Hike, But Seesawed After A Three-Day Run

    Sarepta stock toed the line Monday after a three-day run turned negative following its strong second-quarter report last week and a price-target hike.

  • American City Business Journals3 days ago

    Sarepta may look to bolster pipeline after $250M offering

    Sarepta Therapeutics is planning to raise up to $250 million in a new stock offering, and said it may use some of the proceeds to acquire or license additional drug candidates. The company said that new CEO Douglas Ingram is interested in buying up to $2 million worth of the shares. Proceeds from the offering could be used to license or acquire “complementary products and technologies,” or for a range of other purposes, including to fund clinical trials, commercialization activities and manufacturing, Sarepta said.

  • Barrons.com6 days ago

    [$$] Sarepta's Sales Ramp Up

    The new CEO of Sarepta Therapeutics, pharma industry veteran Douglas Ingram, is bullish on the company’s prospects, and Wall Street is starting to see it his way. Sarepta shares (SRPT) surged 22% last ...

By using Yahoo, you agree that Yahoo and its partners may use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more